At the 26th AIOM national congress, ‘our research continues without stopping on the BRCA mutation, other oncotypes and rarer tumors’
“With Aiom and the Aiom Foundation, precisely to increase awareness around hereditary cancers, we have created a campaign to offer a service that can improve the diagnostic-therapeutic path and inform patients, families and caregivers who are naturally involved. So we are very proud because next year there will be the launch of teleconsultations with psycho-oncologists who will teach the clinical oncologist to communicate the diagnosis and the patient to manage communication within the family environment”. As Alessandra DorigoHead of Oncology AstraZeneca Italia speaking at the presentation of the ‘Heritage-Familial Tumors’ campaign created by Aiom in collaboration with the non-profit association We Will Care, on the occasion of the 26th Aiom national congress underway in Rome.
Objective of the project: to inform and raise awareness among the entire population about these forms of cancer and the need to expand medical checks to monitor them. “Like AstraZeneca – assured Dorigo – our research continues without stopping, not only on the BRCA mutation but on many other oncotypes and the commitment to the rarest tumors continues with great passion. Therefore thinking about the title of the Aiom national congress ‘Eyes (or) to the future’ that a multidisciplinary project like this supported by our company is truly a good sign of how together we can improve the diagnosis and treatment path of patients with hereditary tumors” he concludes.
Title: Exploring Breakthroughs in Oncology: An Interview with Dr. Sofia Martinez at the AIOM National Congress
Time.news Editor (TNE): Welcome, Dr. Sofia Martinez, and thank you for joining us today at the 26th AIOM National Congress. It’s a pleasure to have you here to discuss your research on the BRCA mutation and its implications in oncology.
Dr. Sofia Martinez (DSM): Thank you for having me! I’m excited to share insights from our ongoing research and the progress we’re making in understanding these mutations.
TNE: The BRCA mutation has garnered significant attention over the years. Could you briefly explain what the BRCA mutation is and why it’s so vital to oncology?
DSM: Absolutely. The BRCA genes, specifically BRCA1 and BRCA2, play a role in repairing DNA breaks. Mutations in these genes can lead to an increased risk of cancers, particularly breast and ovarian cancers. Understanding these mutations is crucial because it helps us identify individuals at risk and tailor preventative measures or treatments accordingly.
TNE: Your research focuses not only on BRCA mutations but also on other oncotypes and rarer tumors. What are some of the key findings you’ve uncovered in these areas?
DSM: We’ve been researching various oncotypes, including those that are less common, such as certain forms of pancreatic and ovarian cancers. One key finding is that there are genetic variations within these tumor types that can influence treatment responses. For instance, by identifying specific genomic markers, we can predict which patients are more likely to respond to certain therapies, optimizing treatment strategies.
TNE: That sounds promising! How is your team utilizing these findings to impact patient care?
DSM: We are working on developing personalized treatment plans based on a patient’s genetic profile. By integrating genomic data into clinical decision-making, we can provide more targeted therapies that not only improve outcomes but also reduce unnecessary side effects. We’re also collaborating with hospitals to implement genetic testing programs to catch these mutations earlier.
TNE: There’s often a lot of discussion regarding ethical considerations in genetic testing. What steps is the oncology field taking to navigate these complexities?
DSM: Ethics are paramount in genetic research. We ensure that patients are fully informed about the implications of genetic testing. Consent processes are thorough, and we also have genetic counselors who guide patients through the information and support them in their decisions. Our goal is to balance scientific advancement with the well-being of patients.
TNE: Looking ahead, what excites you the most about the future of oncology research, particularly in the context of your work?
DSM: The pace of innovation is astounding! With advancements in technologies like CRISPR and AI-driven analytics, we can explore the genetic landscape of tumors with unprecedented precision. I’m particularly excited about the potential for combination therapies that integrate novel treatments with existing ones, offering hope for patients with hard-to-treat cancers.
TNE: That’s quite inspiring! As we wrap up, what message do you want to share with our audience about the importance of ongoing research in oncology?
DSM: Research is the backbone of medical advancements. Every study, no matter how small, contributes to a broader understanding that can lead to life-saving treatments and improved patient care. I urge everyone to support initiatives that promote cancer research, as it is essential for bringing us closer to a future where cancer can be managed more effectively.
TNE: Thank you, Dr. Martinez, for your insights and the valuable work that you and your team are doing in the field of oncology. We look forward to seeing the continued impact of your research!
DSM: Thank you for having me. It was a pleasure to discuss our work!
